Aim immunotech announces positive safety data from the third cohort of its phase 1 intranasal clinical trial

Ocala, fla., may 26, 2021 (globe newswire) -- aim immunotech inc. (nyse american: aim) today announced that it has completed dosing of cohort 3 in a phase 1 clinical study to assess the safety, tolerability and biological activity of ampligen as an intranasal therapy, reporting no serious adverse events.
AIM Ratings Summary
AIM Quant Ranking